RESUMO
Immunization with the 69-kD outer membrane protein (OMP) of Bordetella pertussis protected neonatal mice against lethal respiratory challenge with B. pertussis 18323. Active immunization elicited a serum IgG anti-69-kD OMP response at the time of challenge, with IgG anti-69-kD OMP antibodies detected in bronchoalveolar lavage fluid after challenge. Intravenous administration of BPE8, a monoclonal IgG1 anti-69-kD OMP, also protected young mice against B. pertussis challenge. Intravenously injected BPE8 was detected in the lungs of mice at the time of aerosol challenge, suggesting that the presence of specific antibody in the lungs may mediate protection. Thus the 69-kD OMP of B. pertussis is a protective antigen in mice that elicits specific serum antibody that can transude to the lung. The 69-kD OMP was detected in a preparation of a Takeda acellular vaccine by immunoblot analysis and a serum antibody response to the 69-kD OMP was observed in 18-mo-old children boosted with this preparation of Japanese acellular vaccine. Our results demonstrate that the B. pertussis 69-kD OMP is a protective antigen in animals, is immunogenic in humans, and is present in a preparation of acellular pertussis vaccine that is widely used in Japan. These findings indicate that the 69-kD OMP should be seriously considered as a candidate for inclusion in new formulations of antigenically defined acellular pertussis vaccines.
Assuntos
Proteínas da Membrana Bacteriana Externa/metabolismo , Bordetella pertussis/fisiologia , Coqueluche/imunologia , Animais , Anticorpos Monoclonais , Proteínas da Membrana Bacteriana Externa/imunologia , Proteínas da Membrana Bacteriana Externa/isolamento & purificação , Bordetella pertussis/imunologia , Bordetella pertussis/patogenicidade , Imunização , Imunização Passiva , Camundongos , Camundongos Endogâmicos BALB C , Peso MolecularRESUMO
The Sézary syndrome is a frequently lethal disease characterized by circulating malignant cells of thymus-derived (T)-cell origin. The capacity of circulating malignant lymphocytes from patients with this syndrome to synthesize immunoglobulins and to function as helper or suppressor cells regulating immunoglobulin synthesis by bone marrow-derived (B) lymphocytes was determined. Peripheral blood lymphocytes from normal individuals had geometric mean immunoglobulin synthetic rates of 4,910 ng for IgM, 1,270 ng for IgA, and 1,625 ng for IgG per 2 X 10(6) cells in culture with pokeweed mitogen for 7 days. Purified normal B cells had geometric mean synthetic rates of 198 ng for IgM, 145 ng for IgA, and 102 ng for IgG. Leukemic cells from patients with the Sézary syndrome produced essentially no immunoglobulins. Adding normal T cells to normal B cells restored their immunoglobin producing capacity. Leukemic cells from four of five patients tested had a similar capacity to help immunoglobulin synthesis by purified normal B cells. Additionally, Sézary cells from one patient studied induced a nearly 10-fold increase in IgA synthesis by lymphocytes from a child with ataxia telangiectasia and selective IgA deficiency. Furthermore, these Sézary cells induced more than a 500-fold increase in IgG and IgA synthesis by lymphocytes from a child with Nezelof's syndrome. When Sézary cells were added to normal unfractionated lymphocytes, they did not suppress immunoglobulin biosynthesis. In addition, unlike the situation observed when large numbers of normal T cells were added to purified B cells, there was no depression of immunoglobulin synthesis at very high malignant T-cell to B-cell ratios. These data support the view that Sézary T cells do not express suppressor cell activity. The results presented in this paper suggest that neoplastic lymphocytes from the majority of patients with the Sézary syndrome originate from a subset of T cells programmed exclusively for helper-like interactions with B cells in their production of immunoglobulin molecules.
Assuntos
Dermatite Esfoliativa/imunologia , Doenças Linfáticas/imunologia , Linfócitos T/imunologia , Adulto , Idoso , Células Produtoras de Anticorpos/imunologia , Feminino , Humanos , Imunoglobulinas/biossíntese , Masculino , Pessoa de Meia-Idade , Células Neoplásicas Circulantes , SíndromeRESUMO
Serologic data often have a wide range and commonly do not approximate a normal distribution. Means, medians, SDs, or other conventional numerical summaries of antibody data may not adequately or fully describe these complex data. The reverse cumulative distribution plot is a graphic tool that completely displays all the data, allows a rapid visual assessment of important details of the distribution, and simplifies comparison of distributions.
Assuntos
Anticorpos/sangue , Estatística como Assunto , Vacinas/imunologia , Anticorpos Antibacterianos/sangue , Humanos , Vacina contra Coqueluche/imunologiaRESUMO
OBJECTIVE: To examine the relationships between functional assays and antigen-specific enzyme immunoassays in sera from a multicenter trial of 13 different experimental acellular pertussis vaccines and 2 licensed whole-cell vaccines, and to determine whether correlations previously observed among assays of specimens from pertussis patients and whole-cell vaccinees would apply to specimens from infants immunized with purified components in acellular vaccines. METHODS: Postimmunization sera were assayed for immunoglobulin G antibodies to pertussis toxin (PT), filamentous hemagglutinin, pertactin (PRN), and a mixture of types 2 and 3 fimbriae (FIM) by enzyme-linked immunosorbent assay, for whole-cell agglutinins (AGGs) and for PT-neutralizing antibodies by the Chinese hamster ovary (CHO) cell assay. Assay results were compared for individual sera, as well as for geometric mean antibody concentrations or titers (GMTs) calculated by vaccine or overall. RESULTS: For the 15 vaccines, the PT GMTs were highly correlated with the CHO assay GMTs (r = .92), and the FIM GMTs were highly correlated with the AGG GMTs (r = .96). For individual postvaccination sera, there was a significant correlation between the CHO titers and levels of antibody to PT whether the 15 vaccines were considered separately (.59 < or = r < or = .85) or combined (r = .81). For individual sera from infants immunized with the two whole-cell vaccines or any of the four acellular vaccines containing FIM, a strong correlation between AGG titer and FIM antibody was observed whether the vaccines were considered separately (.83 < or = r < or = .91) or together (r = .86). One vaccine without detectable FIM produced a measurable AGG response; for this vaccine, a moderate but significant correlation (R = .58) between PRN antibody and AGG titer was observed. CONCLUSION: These data indicate that appropriate antigen-specific enzyme-linked immunosorbent assays will furnish results similar to those provided by the CHO and AGG assays in the evaluation of the immunogenicity of component vaccines. Antibodies to FIM seem to include the most important AGGs; however, there is evidence that agglutination by PRN antibody may be detected in the absence of antibody to FIM.
Assuntos
Anticorpos Antibacterianos/sangue , Bordetella pertussis/imunologia , Testes Imunológicos , Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Testes de Aglutinação , Animais , Células CHO , Cricetinae , Ensaio de Imunoadsorção Enzimática , Fímbrias Bacterianas/imunologia , Humanos , LactenteRESUMO
OBJECTIVE: To compare the immunogenicity of a licensed conventional whole-cell (WCL) and 13 diphtheria-tetanus-acellular pertussis (DTaP) vaccines that differed in source, method of manufacture, and included antigens; all vaccines included diphtheria and tetanus toxoids. METHODS: Healthy infants were enrolled through six university-based vaccine and treatment evaluation units and were randomized to receive one of the study vaccines at 2, 4, and 6 months of age. Sera were obtained before the first immunization and 1 month after the third immunization and were analyzed for antibody to pertussis toxin (PT), filamentous hemagglutinin, fimbriae, pertactin, and diphtheria and tetanus toxins. Chinese hamster ovary cell toxin neutralization assays were performed, and levels of agglutinating antibodies were determined. RESULTS: Of 2342 infants enrolled, 1942 contributed usable preimmunization and postimmunization serum specimens. Each vaccine produced significant increases in antibodies directed against the included antigens; postimmunization antibody titers differed significantly among the DTaP vaccines. For each evaluated antigen, the majority of DTaP vaccines produced antibody responses that equaled or exceeded those produced by WCL. For some antigens (eg, PT), mean antibody levels by vaccine correlated poorly with the quantity of antigen included in each vaccine; for others (eg., fimbriae), there was a close correlation. CONCLUSION: Although serologic correlates of pertussis immunity are not defined, it is clear that DTaP vaccines can stimulate immune responses that exceed those of licensed whole-cell vaccine with respect to the measured antibodies. Particularly for PT, immunogenicity seems to depend on factors in addition to antigen concentration, possibly including antigen derivation and formulation. No DTaP was most or least immunogenic with respect to all included antigens.
Assuntos
Anticorpos Antibacterianos/sangue , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Toxina Diftérica/imunologia , Vacina contra Difteria, Tétano e Coqueluche/uso terapêutico , Método Duplo-Cego , Fímbrias Bacterianas/imunologia , Hemaglutininas/imunologia , Humanos , Lactente , Toxina Pertussis , Vacina contra Coqueluche/uso terapêutico , Toxina Tetânica/imunologia , Fatores de Virulência de Bordetella/imunologia , Coqueluche/prevenção & controleRESUMO
OBJECTIVE: To compare prospectively the reactogenicity and immunogenicity of two licensed whole-cell pertussis vaccines. METHODS: We conducted a prospective, randomized, double-blinded assessment of two licensed whole-cell pertussis vaccines with diphtheria and tetanus toxoids that were included in a multicenter trial evaluating 13 acellular pertussis vaccines. Infants were immunized at 2, 4, and 6 months of age with a single lot of Lederle (309 infants) or Massachusetts Public Health Biologic Laboratories (MPHBL; 94 infants) vaccine. RESULTS: The group receiving the Lederle vaccine demonstrated significantly higher antibody titers to pertussis toxin by enzyme-linked immunosorbent assay (ELISA) and by the Chinese hamster ovary cell pertussis toxin neutralization assay, and to fimbrial antigens by ELISA, as well as higher mean agglutinin titers. In contrast, the group receiving the MPHBL vaccine demonstrated higher ELISA antibody levels to filamentous hemagglutinin and pertactin. Similar differences were observed in the proportions of vaccinees seroconverting to these antigens. Rates of systemic and local reactions were relatively low for both vaccines. Although the Lederle product had substantially lower reactogenicity in this study than previously reported for that vaccine, the MPHBL vaccine was significantly less reactogenic in nearly all clinical categories. CONCLUSION: The two whole-cell vaccines demonstrated statistically significant differences in postimmunization antibody levels to all six evaluated pertussis antigens. Whether these statistically significant differences in antibody levels have clinical relevance is not clear. Rates of nearly all local and systemic reactions were significantly lower among the MPHBL group than the Lederle group. Licensed whole-cell diphtheria-tetanus-pertussis vaccines produced by different manufacturers cannot be assumed to be similar in reactogenicity or immunogenicity.
Assuntos
Anticorpos Antibacterianos/sangue , Vacina contra Coqueluche/efeitos adversos , Coqueluche/imunologia , Bordetella pertussis/imunologia , Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Método Duplo-Cego , Febre/etiologia , Humanos , Lactente , Toxina Pertussis , Vacina contra Coqueluche/imunologia , Estudos Prospectivos , Fatores de Virulência de Bordetella/imunologiaRESUMO
OBJECTIVE: To describe and evaluate the assays used to measure the antibody responses in infants to 13 experimental acellular pertussis vaccines and 2 licensed whole-cell pertussis vaccines. METHODS: During a 53-week period, preimmunization and postimmunization sera were assayed for immunoglobulin G antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and a mixture of type 2 and type 3 fimbriae by enzyme-linked immunosorbent assay (ELISA), for whole-cell agglutinins (AGG), and for pertussis toxin-neutralizing antibodies by the Chinese hamster ovary cell assay. All ELISA reagents were characterized to assure antigen and isotype specificity of the assays. Intralaboratory reproducibility and temporal stability were evaluated by analysis of results of control sera and by assessment of the response to the control whole-cell vaccine. Interlaboratory reproducibility was assessed by repeating the assays on preimmunization and postimmunization sera for 10% of the infants in a second laboratory. RESULTS: For control sera having antibody concentrations at least four times the minimum level of detection, the coefficients of variation within and between the ELISAs consistently were less than 20%. Trend analysis indicated that none of the assays drifted by more than 20% during the study period, and no significant drift was seen in the response to the control whole-cell vaccine. Results from the two laboratories correlated well; correlation coefficients were .93 or greater for the four ELISAs, .79 for the Chinese hamster ovary cell assay, and .82 for the AGG assay. For four of the six assays, there was either no difference or a modest (< 15%) difference in the geometric mean values for sera tested in both laboratories. Larger quantitative differences were observed for the AGG (45% difference) and pertactin (61% difference) assays. CONCLUSION: Assay reproducibility and stability indicate that the standardized methods can be transferred between laboratories, and that the results accrued during a 1-year period for the 15 vaccines can be compared.
Assuntos
Anticorpos Antibacterianos/sangue , Bordetella pertussis/imunologia , Imunoensaio/normas , Vacina contra Coqueluche/imunologia , Testes de Aglutinação/normas , Animais , Células CHO , Cricetinae , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Ensaio de Imunoadsorção Enzimática/normas , Humanos , Lactente , Laboratórios/normas , Toxina Pertussis , Reprodutibilidade dos Testes , Fatores de Virulência de Bordetella/imunologiaRESUMO
OBJECTIVE: To evaluate the effect of maternally derived antibody on the immunogenicity and reactogenicity of acellular (DTaP) or whole-cell (DTP) pertussis vaccine with diphtheria and tetanus toxoids combined. METHODS: A total of 2342 infants were randomized to receive one of 13 DTaP or 2 DTP vaccines at 2, 4, and 6 months of age. The correlation between preimmunization and postimmunization antibody after three doses of vaccine and the relation between preimmunization antibody and adverse reactions after the first immunization were modeled by linear regression. RESULTS: After DTP but not DTaP, higher levels of preexisting antibody were associated with substantial (28% to 56%) reductions in the subsequent antibody response to pertussis toxin (PT). For other pertussis antibodies, modest inverse correlations were seen between preexisting antibody concentrations and most postimmunization antibody responses (resulting in 8% to 18% reductions in postimmunization antibody) for both DTP and DTaP. There was no consistent association in any DTP or DTaP group between adverse reactions and preimmunization antibody levels. CONCLUSION: The PT antibody response to DTaP, unlike DTP, is not adversely affected by preexisting antibody to PT. Inhibitory effects with respect to other antibodies, seen with both DTP and DTaP, were relatively modest. Our data suggest that the use of acellular pertussis vaccines in adults, which could confer higher levels of antibody in women before pregnancy, would be unlikely to adversely affect pertussis antibody responses after DTaP among infants born to mothers with high antibody levels.
Assuntos
Anticorpos Antibacterianos/sangue , Bordetella pertussis/imunologia , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Imunidade Materno-Adquirida/imunologia , Lactente , Modelos Lineares , Vacina contra Coqueluche/efeitos adversosRESUMO
We prospectively compared the ability of anti-venom and edrophonium (Tensilon) to improve paralytic symptoms in 8 patients envenomed by the Philippine cobra (Naja naja philippinensis). Twenty, 50 or 100 ml of Philippine cobra antivenom were administered in a double-blind fashion by constant intravenous infusion over 30 min. Even the largest dose of antivenom failed to produce marked improvement within 2 h, though enzyme-linked immunosorbent assays and neutralization tests demonstrated that it possessed high titres of anti-neurotoxin antibodies. Tensilon given at 2 h was significantly more effective than antivenom at increasing the duration of upward gaze (78 +/- 28 vs 43 +/- 26 sec, P less than 0.001), and either completely reversed or markedly decreased paralysis in every patient. The Tensilon test should be given to all patients with paralytic envenoming by cobras, and anticholinesterases administered to those with a positive response.
Assuntos
Antivenenos/uso terapêutico , Edrofônio/uso terapêutico , Paralisia/tratamento farmacológico , Mordeduras de Serpentes/tratamento farmacológico , Adolescente , Adulto , Proteínas Neurotóxicas de Elapídeos/antagonistas & inibidores , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes de Neutralização , Estudos Prospectivos , Ensaios Clínicos Controlados Aleatórios como Assunto , Mordeduras de Serpentes/complicaçõesAssuntos
Bordetella pertussis/isolamento & purificação , Reação em Cadeia da Polimerase , Coqueluche/diagnóstico , Bordetella pertussis/genética , Primers do DNA , DNA Bacteriano/análise , Reações Falso-Negativas , Reações Falso-Positivas , Humanos , Nasofaringe/microbiologia , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Manejo de EspécimesRESUMO
An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consensus opinion on existing gaps in understanding standardization of pertussis assays used for serodiagnosis and vaccine evaluation; and (4) to search for a multicenter process for addressing these priority gaps. Presentations and discussions by content experts addressed these objectives. A prioritized list of action items to improve standardization and harmonization of pertussis assays was identified during a group discussion at the end of the meeting. The major items included: (1) to identify a group that will organize, prepare, maintain, and distribute proficiency panels and key reagents such as reference and control sera; (2) to encourage the development and identification of one or more reference laboratories that can serve as an anchor and resource for other laboratories; (3) to define a performance-based assay method that can serve as a reference point for evaluating laboratory differences; (4) to develop guidance on quality of other reagents, e.g., pertussis toxin and other antigens, and methods to demonstrate their suitability; (5) to establish an international working group to harmonize the criteria to evaluate the results obtained on reference and proficiency panel sera; (6) to create an inventory to determine the amount of appropriate and well-characterized sera that are available globally to be used as bridging reagents for vaccine licensure; and (7) to seek specific guidance from regulatory authorities regarding the expectations and requirements for the licensure of new multicomponent pertussis vaccines.
Assuntos
Bordetella pertussis/imunologia , Técnicas de Laboratório Clínico/normas , Coqueluche/diagnóstico , Coqueluche/prevenção & controle , Centers for Disease Control and Prevention, U.S. , Humanos , Estados Unidos , Coqueluche/epidemiologia , Coqueluche/imunologiaRESUMO
The Center for Biologics Evaluation and Research within the U.S. Food and Drug Administration has prepared a new U.S. Standard Pertussis Vaccine. Whole cell pertussis vaccine concentrate was diluted in 5% (w/v) lactose and lyophilized. The preparation was tested for toxicity, sterility, heterogeneity and residual moisture. Based on data from an international collaborative study involving 11 laboratories, the potency was estimated in relation to the U.S. Master Standard Pertussis Vaccine, Lot 4 and the International Standard for Pertussis Vaccine, Lot 2. The potency of the preparation was defined to be 90 units per ampoule. When reconstituted and stored according to instructions, no significant change in potency was observed in the 14 days following reconstitution. This material was shown to be suitable for a pertussis vaccine standard and accordingly it was designated as U.S. Standard Pertussis Vaccine, Lot 11 on March 22, 1994.
Assuntos
Vacina contra Coqueluche/normas , Animais , Bioensaio , Fenômenos Químicos , Físico-Química , Liofilização , Humanos , Camundongos , Pessoa de Meia-Idade , Vacina contra Coqueluche/isolamento & purificação , Preservação Biológica , Padrões de Referência , Reprodutibilidade dos Testes , Estados UnidosRESUMO
Previous results from our laboratory demonstrated that purified lymphocytosis-promoting factor (LPF), a protein toxin from Bordetella pertussis, inhibited the migration of murine macrophages in vitro. The current study examined the in vivo effects of LPF on mononuclear phagocyte circulation and response to an inflammatory stimulus. Intravenous injection of mice with 200 ng of LPF produced a prolonged monocytosis which peaked with a fivefold increase on day 5 after injection. LPF (200 ng) also inhibited by more than 75% the increase in peritoneal inflammatory macrophages induced by intraperitoneal injection of thioglycolate broth, phytohemagglutinin, or paraffin oil. The inhibition was significant when thioglycolate was given 1 h or 2 or 4 days after LPF but not when thioglycolate was given 2 or 4 days before LPF. The LPF-induced monocytosis on day 5 after injections was not altered by the intraperitoneal injection of thioglycolate broth. The leukocytosis-promoting and macrophage-inhibiting properties of LPF were the same in N:NIH(S) and C3H/HeJ mice. Treatments of LPF that reduced the leukocytosis-promoting effect of LPF also reduced the ability of LPF to inhibit the macrophage response. LPF doses sufficient to induce leukocytosis (greater than or equal to 25 ng) significantly inhibited the thioglycolate-induced increase in peritoneal macrophages. The results indicate that coincident with an LPF-induced monocytosis is a reduction in the number of mononuclear phagocytes at a site of inflammation. An in vivo inhibition of mononuclear phagocyte migration would explain both effects of LPF and is consistent with the in vitro inhibition of macrophage migration by LPF.
Assuntos
Toxinas Bacterianas/farmacologia , Bordetella pertussis/imunologia , Inflamação/imunologia , Monócitos/efeitos dos fármacos , Fagócitos/efeitos dos fármacos , Animais , Inibição de Migração Celular , Relação Dose-Resposta Imunológica , Feminino , Contagem de Leucócitos , Macrófagos/imunologia , Camundongos , Monócitos/imunologia , Toxina Pertussis , Fagócitos/imunologia , Tioglicolatos/farmacologia , Fatores de Virulência de BordetellaRESUMO
Lymphocytosis promoting factor (LPF) is a protein toxin which may have a role in the pathogenesis of pertussis. Previous results from our laboratory demonstrated that LPF inhibited random migration and chemotaxis of resident peritoneal macrophages, but had little or no effect on macrophage viability, adherence, superoxide anion release, or Fc-mediated phagocytosis. The current experiments have examined mononuclear phagocyte function in mice treated with LPF. Intravenous injection of mice with 200 ng LPF induced a prolonged monocytosis which peaked with a five-fold increase on the fifth day after injection. LPF (200 ng) also inhibited the increase in peritoneal macrophages induced by the intraperitoneal injection of either thioglycolate broth, phytohemagglutinin, or paraffin oil. The LPF-induced monocytosis on the fifth day after injections was not altered by the intraperitoneal injection of thioglycolate broth. LPF doses sufficient to induce leukocytosis (greater than or equal to 25 ng) significantly inhibited the increase in peritoneal macrophages induced by an inflammatory agent. These observed in vitro and in vivo effects of LPF were lost when LPF was subjected to treatments that eliminated its leukocytosis-promoting activity. The results indicate that coincident with an LPF-induced monocytosis is a reduction in the number of macrophages at a site of inflammation. An in vivo inhibition of mononuclear phagocyte migration would explain both of these effects of LPF, and is consistent with the in vitro inhibition of macrophage migration. The results suggest that a possible role for LPF in pathogenesis is the inhibition of macrophage migration to the site of Bordetella pertussis infection.
Assuntos
Bordetella pertussis/fisiologia , Linfocitose/etiologia , Toxina Pertussis , Fagócitos/efeitos dos fármacos , Fatores de Virulência de Bordetella/farmacologia , Animais , Feminino , Inflamação/patologia , Macrófagos/fisiologia , Camundongos , Fagócitos/fisiologia , Coqueluche/etiologiaRESUMO
To evaluate the comparability of immunoassays, the Center for Biologics Evaluation and Research organized an international collaborative study in which 33 laboratories participated. For a coded panel of 21 samples, each laboratory measured IgG antibodies to specific proteins of Bordetella pertussis using assay systems currently in place. Analyses were performed to evaluate the assay precision and the quantitative agreement among laboratories. Data from a subset of 12 laboratories are used to illustrate points relevant to the use of immunoassays in seven vaccine efficacy studies. Differences among the laboratories in assay precision for samples with known two-fold differences indicate that serological case definitions must take into consideration the characteristics of the assays and the concentration of antibody in the samples. Assays performed in different laboratories to assess vaccine immunogenicity may generate similar results but critical comparisons will probably require samples to be tested in the same laboratory at the same time.
Assuntos
Anticorpos Antibacterianos/sangue , Bordetella pertussis/imunologia , Ensaio de Imunoadsorção Enzimática/normas , Adesinas Bacterianas/imunologia , Antígenos de Bactérias/imunologia , Proteínas da Membrana Bacteriana Externa/imunologia , Hemaglutininas/imunologia , Humanos , Valores de Referência , Fatores de Virulência de Bordetella/imunologiaRESUMO
Acellular pertussis vaccines are being evaluated in multiple clinical studies, and human immunogenicity data will likely be pivotal in the appraisal of vaccine responses between populations and the responses to different vaccine combinations. Antibody response to pertussis antigens is also used in the diagnosis of pertussis. An international study was designed to assess the comparability of data generated in different laboratories by enzyme-linked immunosorbent assays (ELISAs). Thirty-three participating laboratories were asked to quantitate specific antibody to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), or fimbrial proteins (FIM) in 21 samples. Samples were to be assayed in triplicate in five independent assays by each ELISA routinely performed in the laboratory to assess intra-assay, interassay, and population variability. The mean sample values were used to compare quantitative results among the laboratories. Thirteen of the 32 laboratories which submitted evaluable data for an assay to measure antibodies to PT, 12 of 30 laboratories with assays for FHA, 10 of 17 laboratories with assays for PRN, and 6 of 13 laboratories with assays for FIM maintained a coefficient of variation below 20% for 75% of the samples tested. Assays that measure antibodies to FIM appear to be less precise than the other assays. Precision varied among laboratories that used similar methods. The relative values of intra- and interassay variabilities were not consistent for a given assay within a laboratory, indicating that the sources of these variability components may be unrelated. Precision and agreement appeared less reliable for samples with low antibody levels. Ranking and regression analyses suggest that some laboratories generated comparable quantitative results, although direct comparison or combination of results from different laboratories remains difficult to support. Calibration to the U.S. Reference Pertussis Antisera appears to have been successful at standardizing the results in some laboratories. Statistical analyses are affected by assay precision and are not necessarily reliable sole predictors of biologically relevant differences in quantitative results. If results from different laboratories must be compared, appropriate studies of precision and quantitative agreement should be conducted to support the specific comparisons.
Assuntos
Anticorpos Antibacterianos/análise , Antígenos de Bactérias/imunologia , Bordetella pertussis/imunologia , Ensaio de Imunoadsorção Enzimática/normas , Anticorpos Antibacterianos/sangue , Humanos , Variações Dependentes do Observador , Vacina contra Coqueluche/normas , Análise de Regressão , Reprodutibilidade dos TestesRESUMO
Elevated agglutinin titers have been shown to correlate with protection from disease following whole-cell pertussis vaccination, but the isotype and antigen specificity of human agglutinating antibodies is unknown. In 13 immunoassays, immunoglobulin G antifimbria antibodies had the strongest correlation with agglutinin titers following culture-proven infection with Bordetella pertussis (R' = 0.79; P < 0.0001) and following whole-cell pertussis vaccination (R' = 0.87, P < 0.0001).
Assuntos
Aglutininas/análise , Anticorpos Antibacterianos/análise , Epitopos , Isotipos de Imunoglobulinas/análise , Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Ensaio de Imunoadsorção Enzimática , Humanos , VacinaçãoRESUMO
One hundred twenty male U.S. Marine Corps trainees with histories of at least 7 days of cough underwent evaluation for Bordetella pertussis infection by culture, B. pertussis-specific polymerase chain reaction (PCR) analysis, and serology. Antibody levels in preexposure, acute-phase, and convalescent-phase serum samples were measured in a microagglutination assay and in enzyme linked immunosorbent assays (ELISAs) for IgG and IgA antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3. Culture and PCR analysis revealed that none of the patients were positive for B. pertussis; however, 20 of 120 trainees had serological evidence of B. pertussis infection. Of these cases, one was confirmed by a rise in the level of antibody to pertussis toxin, and six were classified as probable by increases in levels of antibodies measured by two or more assays. Of the 20 individuals with serological evidence of infection, 16 had rises in levels of antibodies to fimbriae or agglutinating antibodies. The utility of ELISA for detecting antibodies to fimbriae and the microagglutination assay for diagnosing pertussis in adults should be evaluated by application to larger and more diverse study populations. These results indicate that pertussis should be considered in the diagnosis of coughing illness in military populations.
Assuntos
Proteínas de Fímbrias , Militares , Fatores de Virulência de Bordetella , Coqueluche/epidemiologia , Adesinas Bacterianas/imunologia , Adolescente , Adulto , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/imunologia , Proteínas de Bactérias/imunologia , Bordetella pertussis , Ensaio de Imunoadsorção Enzimática , Hemaglutininas/imunologia , Humanos , Masculino , Projetos Piloto , Reação em Cadeia da Polimerase , Porinas/genética , Estados Unidos , Coqueluche/diagnóstico , Coqueluche/microbiologiaRESUMO
When WBC264-9C cells are preincubated with pertussis toxin, chemotaxis is inhibited and ADP-ribosylation of a membrane protein with a subunit Mr 41,000 is observed. Both the inhibition of chemotaxis and the ADP-ribosylation by pertussis toxin display a similar time lag, temperature dependence, and pertussis toxin-concentration dependence. Although the inhibition of chemotaxis and the ADP-ribosylation of the membrane protein are qualitatively correlated, nearly complete inhibition of chemotaxis occurs when there is only partial ADP-ribosylation of the membrane protein. Pertussis toxin-catalyzed ADP-ribosylation of the Mr 41,000 protein in WBC264-9C membranes is stimulated by GDP, GTP, and to a lesser extent by GMP; the nonhydrolyzable GTP analog guanosine 5'-[beta, gamma-imido]triphosphate has no effect. WBC264-9C membranes have a high-affinity GTPase activity, which is partially inhibited in membranes from pertussis toxin-treated cells. Neither GTPase activity nor adenylate cyclase activity in membranes from WBC264-9C cells is affected by fMet-Leu-Phe, an attractant for these cells. Our results suggest that a guanine nucleotide binding protein may be involved in chemotaxis, but they do not indicate an involvement of adenylate cyclase.